Gastrointestinal stromal tumors: Who should get imatinib and for how long?

Advances in Surgery

Volumn 48, Issue 1, 2014, Pages 165-183

  Balachandran, Vinod P ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Oncogenic kinase mutation; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADJUVANT CHEMOTHERAPY; DRUG RESISTANCE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENETICS; HUMAN; METASTASIS; MUTATION; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84906355351     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2014.05.014     Document Type: Review

References (56)

1. Ducimetiere F., Lurkin A., Ranchere-Vince D., et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011, 6:e20294.
2. Joensuu H., Hohenberger P., Corless C.L. Gastrointestinal stromal tumour. Lancet 2013, 382:973-983.
3. Joensuu H., Vehtari A., Riihimaki J., et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012, 13:265-274.
4. Ng E.H., Pollock R.E., Munsell M.F., et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68-77.
5. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
6. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
7. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
8. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
9. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660-667.
10. Joensuu H., DeMatteo R.P. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012, 63:247-258.
11. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEngl J Med 2001, 344:1052-1056.
12. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
13. Verweij J., van Oosterom A., Blay J.-Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
14. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEngl J Med 2002, 347:472-480.
15. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JClin Oncol 2008, 26:620-625.
16. Antman K., Crowley J., Balcerzak S.P., et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. JClin Oncol 1993, 11:1276-1285.
17. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. JClin Oncol 2008, 26:626.
18. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103.
19. Heinrich M.C., Owzar K., Corless C.L., et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. JClin Oncol 2008, 26:5360-5367.
20. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. JClin Oncol 2010, 28:1247-1253.
21. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. JClin Oncol 2007, 25:1760-1764.
22. Van den Abbeele A.D., Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(Suppl 5):S60-S65.
23. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005, 7:307-311.
24. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. JClin Oncol 2007, 25:1753-1759.
25. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and invitro sensitivity to imatinib. JClin Oncol 2005, 23:5357-5364.
26. Blay J.Y., Le Cesne A., Ray-Coquard I., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. JClin Oncol 2007, 25:1107-1113.
27. Le Cesne A., Ray-Coquard I., Bui B.N., et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11:942-949.
28. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. JClin Oncol 2006, 24:2325-2331.
29. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007, 245:341-346.
30. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005, 41:1751-1757.
31. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
32. Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:295-302.
33. Balachandran V.P., Cavnar M.J., Zeng S., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100.
34. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
35. Cavnar M.J., Zeng S., Kim T.S., et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. JExp Med 2013, 210:2873-2886.
36. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999, 23:82-87.
37. Miettinen M., El-Rifai W., H L Sobin L., et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002, 33:478-483.
38. DeMatteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112:608-615.
39. Fletcher C.D.M., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
40. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
41. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008, 39:1411-1419.
42. Gold J., Gönen M., Gutiérrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10:1045-1052.
43. Rossi S., Miceli R., Messerini L., et al. Natural history of Imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011, 35:1646-1656.
44. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. JClin Oncol 2002, 20:3898-3905.
45. Corless C.L., Ballman K.V., Antonescu C.R., et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI Stromal Tumor: the ACOSOG Z9001 trial. JClin Oncol 2014, 32:1563-1570.
46. McCarter M.D., Antonescu C.R., Ballman K.V., et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. JAm Coll Surg 2012, 215:53-59. [discussion: 59-60].
47. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup phase 2 trial. Ann Surg 2013, 258:422-429.
48. DeMatteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
49. Li J., Gong J.F., Wu A.W., et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011, 37:319-324.
50. Casali P.G., Le Cesne A., Velasco A.P., et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. JClin Oncol 2013, 31(Suppl). [abstract: 10500].
51. Joensuu H., Eriksson M., Sundby Hall K., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307:1265-1272.
52. Reichardt P., Hartmann J.T., Sundby Hall K., et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment - the first analysis in the SSGXVIII/AIO trial patient population. Eur J Cancer 2011, 47:15.
53. Kang Y.K., Kang B.W., Im S.A., et al. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. Cancer Chemother Pharmacol 2013, 71:43-51.
54. Eisenberg B.L., Harris J., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. JSurg Oncol 2009, 99:42-47.
55. Mcauliffe J.C., Hunt K.K., Lazar A.J.F., et al. Arandomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16:910-919.
56. von Mehren M., Benjamin R.S., Bui M.M., et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. JNatl Compr Canc Netw 2012, 10:951-960.